Literature DB >> 23890028

An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia.

Rodrigo A Fraga-Silva1, Fabiana P Costa-Fraga, Silvia Q Savergnini, Frederico B De Sousa, Fabrizio Montecucco, Daniele da Silva, Ruben D Sinisterra, François Mach, Nikolaos Stergiopulos, Rafaela F da Silva, Robson A S Santos.   

Abstract

INTRODUCTION: The renin angiotensin system plays a crucial role in erectile function. It has been shown that elevated angiotensin-II levels contribute to the development of erectile dysfunction (ED). Oppositely, angiotensin-(1-7) (Ang-[1-7]) mediates penile erection by activation of receptor Mas. Recently, we have developed a formulation based on Ang-(1-7) inclusion in cyclodextrin (CyD) [Ang-(1-7)-CyD], which allows for the oral administration of Ang-(1-7). AIM: In the present study, we evaluated the effects of chronic treatment with Ang-(1-7)-CyD on penile fibrosis, oxidative stress, and endothelial function in hypercholesterolemic mice.
METHODS: Apolipoprotein(Apo)E-/- mice fed a Western-type diet for 11 weeks received Ang-(1-7)-CyD or vehicle during the final 3 weeks. Collagen content and reactive oxygen species (ROS) production within the corpus cavernosum were evaluated by Sirius red and dihydroethidium staining, respectively. Protein expression of neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) subunits (p67-phox and p22-phox), and AT1 and Mas receptors in the penis was assessed by Western blotting. Nitric oxide (NO) production was measured by Griess assay in the mice serum. Cavernosal strips were mounted in an isometric organ bath to evaluate the endothelial function. MAIN OUTCOME MEASURES: The effect of Ang-(1-7)-CyD treatment on penile fibrosis, oxidative stress, and endothelial function in hypercholesterolemia-induced ED.
RESULTS: Ang-(1-7)-CyD treatment reduced collagen content in the corpus cavernosum of ApoE-/- mice. This effect was associated with an attenuation of ROS production and a diminished expression of NADPH. Furthermore, Ang-(1-7)-CyD treatment augmented the expression of nNOS and eNOS in the penis and elevated vascular NO production. Importantly, these effects were accompanied by an improvement in cavernosal endothelial function.
CONCLUSION: Long-term treatment with Ang-(1-7)-CyD reduces penile fibrosis associated with attenuation of oxidative stress. Additionally, cavernosal endothelial function in hypercholesterolemic mice was markedly improved. These results suggest that Ang-(1-7)-CyD might have significant therapeutic benefits for the treatment of erectile dysfunction.
© 2013 International Society for Sexual Medicine.

Entities:  

Keywords:  Angiotensin-(1-7); Erectile Dysfunction; Fibrosis; Hydroxypropyl-Cyclodextrin; Hypercholesterolemia; Mas Receptor; Oxidative Stress

Mesh:

Substances:

Year:  2013        PMID: 23890028     DOI: 10.1111/jsm.12262

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  9 in total

1.  Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetes.

Authors:  Neha Singh; Goutham Vasam; Rahul Pawar; Yagna P R Jarajapu
Journal:  J Sex Med       Date:  2014-06-23       Impact factor: 3.802

2.  Analysis of erectile responses to bradykinin in the anesthetized rat.

Authors:  Justin A Edward; Edward A Pankey; Ryan C Jupiter; George F Lasker; Daniel Yoo; Vishwaradh G Reddy; Taylor C Peak; Insun Chong; Mark R Jones; Samuel V Feintech; Sarah H Lindsey; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-08       Impact factor: 4.733

Review 3.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 4.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Senescent Cells Impair Erectile Function through Induction of Endothelial Dysfunction and Nerve Injury in Mice.

Authors:  Hiroaki Nishimatsu; Etsu Suzuki; Yasuho Saito; Aya Niimi; Akira Nomiya; Hiroshi Fukuhara; Haruki Kume; Yukio Homma
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 6.  Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.

Authors:  Tomas Rajtik; Peter Galis; Linda Bartosova; Ludovit Paulis; Eva Goncalvesova; Jan Klimas
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

7.  Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice.

Authors:  Rodrigo Araujo Fraga-Silva; Fabiana Pereira Costa-Fraga; Fabrizio Montecucco; Younouss Faye; Silvia Quintao Savergnini; Sébastien Lenglet; François Mach; Sabine Steffens; Nikolaos Stergiopulos; Robson Augusto Souza dos Santos; Rafaela Fernandes da Silva
Journal:  Clin Dev Immunol       Date:  2013-11-03

8.  Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes.

Authors:  Mariam H M Yousif; Batoul Makki; Ahmed Z El-Hashim; Saghir Akhtar; Ibrahim F Benter
Journal:  J Diabetes Res       Date:  2014-09-16       Impact factor: 4.011

9.  Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis.

Authors:  D S Skiba; R Nosalski; T P Mikolajczyk; M Siedlinski; F J Rios; A C Montezano; J Jawien; R Olszanecki; R Korbut; M Czesnikiewicz-Guzik; R M Touyz; T J Guzik
Journal:  Br J Pharmacol       Date:  2017-02-01       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.